This study comprehensively evaluates the safety and immunological profile of a single subretinal administration of recombinant adeno-associated virus (rAAV) encoding wild-type RPE65 in dogs affected by inherited retinal degeneration due to RPE65 deficiency. The research focuses on systemic and ocular immune responses, vector biodistribution, and long-term tolerability following gene transfer. A total of 29 eyes from 19 affected dogs received a single subretinal injection of rAAV-RPE65 using various pseudotypes (AAV2/2, 2/1, 2/5), promoters (CBA, RPE08), and cDNA sources (canine or human). Additional controls included intravitreal injections and untreated eyes.
No significant systemic toxicity was observed throughout the follow-up period, which extended up to five years post-treatment. All dogs remained clinically healthy, with normal behavior, appetite, and ophthalmic examination findings. Only one dog developed transient intraocular inflammation immediately after injection, linked to an inadequately purified vector batch—confirmed by protein gel electrophoresis showing impurities. This inflammation resolved with short-term corticosteroid therapy, and vision recovery proceeded normally in that eye.SLFN11 Antibody Biological Activity No other cases of severe ocular inflammation were reported in any treated or control eyes.
Serological analysis revealed that all treated dogs exhibited increased antibody titers against AAV2/2 capsid proteins compared to pre-treatment levels. However, this response was not correlated with treatment success or functional outcomes. Dogs with high pre-existing antibodies showed no greater risk of adverse effects, and those with low baseline titers demonstrated similar functional improvement. Notably, the route of delivery—subretinal versus intravitreal—did not influence antibody production, indicating that local ocular delivery does not significantly amplify systemic immune responses.
Crucially, no specific anti-RPE65 immune response was detected in serum or intraocular fluids.4-Bromophthalic acid site Enzyme-linked immunosorbent assays (ELISA) using GST-RPE65 fusion protein as antigen showed no significant reactivity above background in any sample.PMID:34328581 Western blot analysis confirmed the absence of detectable anti-RPE65 antibodies, even in animals that had experienced mild inflammatory reactions. This suggests that the introduced RPE65 protein is not immunogenic in this context, likely due to its expression within the immune-privileged retina and the lack of antigen-presenting cell activation.
Extraocular transgene expression was rigorously assessed via PCR and RT-PCR on tissues including kidney, liver, heart, lung, brain, lymph nodes, ovary/testis, bone marrow, and extraocular muscle collected at terminal sacrifice (3–12 months post-treatment). No amplification of wild-type RPE65 cDNA was detected in any tissue, confirming the absence of vector spread beyond the retina. Similarly, immunocytochemistry failed to reveal RPE65 protein in optic nerve or other non-retinal structures.
These findings collectively demonstrate that subretinal rAAV-RPE65 gene therapy is well tolerated in dogs with no evidence of systemic toxicity, widespread immune activation, or off-target transgene expression. The localized nature of both functional rescue and protein expression, coupled with minimal immunogenicity, supports a favorable safety profile. This robust safety record across multiple time points—including long-term monitoring—provides strong preclinical justification for advancing this therapy into human clinical trials for Leber congenital amaurosis caused by RPE65 mutations.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com